The Treatment of Moderate and Severe Chronic Plaque Psoriasis With Biologics and Biosimilar Drugs

Abstract

Psoriasis is a chronic, immune-mediated inflammatory skin disease. The condition greatly affects people’s quality of life to the extent that it could be life-ruining and stigmatizing. A better understanding of psoriasis pathophysiology allowed the development of targeted therapies, including biologics and biosimilars which are recommended as an option for moderate to severe plaque psoriasis. Our results have shown that administration of biologics (adalimumab and secukinumab) and adalimumab biosimilar led to a significant improvement in the PASI response after 16 weeks. Most patients who have been treated for more than a year have the same PASI response.